Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D supplementation in heart failure with preserved or moderately reduced ejection fraction
2018-001488-21Phase 4Terminated
- Sponsor
- Sergio Aleman
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF) and Vitamin D deficiency (VDD) comparing Vitamin D (calcifediol/Hidroferol) with Placebo (2 arms). Primary endpoints: Left ventricular longitudinal strain change and Circumferential ventricular strain change. Started Jul 2018; status: terminated.
02
Drugs
calcifediol
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on 2018-001488-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001488-21.